Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study
Advanced stage primary hepatocellular carcinoma (HCC) accounts for more than half of all cases worldwide. Poor prognosis is mainly attributed to intrahepatic tumor burden caused by high-risk factors, including Vp4-portal vein tumor thrombosis or tumor occupancy of >50% of the liver. In 2020, the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2022-01-01
|
| Series: | Visualized Cancer Medicine |
| Subjects: | |
| Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2022/01/vcm20220002/vcm20220002.html |
| _version_ | 1797333785768886272 |
|---|---|
| author | Lyu Ning Zhao Ming |
| author_facet | Lyu Ning Zhao Ming |
| author_sort | Lyu Ning |
| collection | DOAJ |
| description | Advanced stage primary hepatocellular carcinoma (HCC) accounts for more than half of all cases worldwide. Poor prognosis is mainly attributed to intrahepatic tumor burden caused by high-risk factors, including Vp4-portal vein tumor thrombosis or tumor occupancy of >50% of the liver. In 2020, the combination of a VEGF/PD-L1 blocker was superior to a single tyrosine kinase inhibitor and associated with a median overall survival of 19.2 months. However, overall survival dramatically declined from 19.2 months to 7.6 months for patients with high-risk factors. In this present study, the FOHAIC-1 trial, interventional hepatic arterial infusion chemotherapy of FOLFOX (HAIC-FO) showed favorable survival outcomes in patients with high-risk advanced HCC. Compared with a tyrosine kinase inhibitor, in the high-risk subgroup, HAIC-FO achieved an overall survival of 10.8 months (vs. 5.7 months, hazard ratio 0.343, 95% confidence interval, 0.219–0.538). This study also observed disease downstaging in 16 (16/130) patients who received HAIC-FO; 15 (93.8%) patients received curative or regional treatments afterward. Therefore, for advanced HCC with localized high-risk factors, the clinical efficacy of HAIC-FO is significant and may be a better option than systemic therapies. |
| first_indexed | 2024-03-08T08:11:07Z |
| format | Article |
| id | doaj.art-064153e9e5424105a565c385dc36dbed |
| institution | Directory Open Access Journal |
| issn | 2740-4218 |
| language | English |
| last_indexed | 2024-03-08T08:11:07Z |
| publishDate | 2022-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | Visualized Cancer Medicine |
| spelling | doaj.art-064153e9e5424105a565c385dc36dbed2024-02-02T08:40:36ZengEDP SciencesVisualized Cancer Medicine2740-42182022-01-013E110.1051/vcm/2022003vcm20220002Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 studyLyu Ning0Zhao Ming1Department of Minimally Invasive and Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer CenterDepartment of Minimally Invasive and Interventional Therapy, Liver Cancer Study and Service Group, Sun Yat-Sen University Cancer CenterAdvanced stage primary hepatocellular carcinoma (HCC) accounts for more than half of all cases worldwide. Poor prognosis is mainly attributed to intrahepatic tumor burden caused by high-risk factors, including Vp4-portal vein tumor thrombosis or tumor occupancy of >50% of the liver. In 2020, the combination of a VEGF/PD-L1 blocker was superior to a single tyrosine kinase inhibitor and associated with a median overall survival of 19.2 months. However, overall survival dramatically declined from 19.2 months to 7.6 months for patients with high-risk factors. In this present study, the FOHAIC-1 trial, interventional hepatic arterial infusion chemotherapy of FOLFOX (HAIC-FO) showed favorable survival outcomes in patients with high-risk advanced HCC. Compared with a tyrosine kinase inhibitor, in the high-risk subgroup, HAIC-FO achieved an overall survival of 10.8 months (vs. 5.7 months, hazard ratio 0.343, 95% confidence interval, 0.219–0.538). This study also observed disease downstaging in 16 (16/130) patients who received HAIC-FO; 15 (93.8%) patients received curative or regional treatments afterward. Therefore, for advanced HCC with localized high-risk factors, the clinical efficacy of HAIC-FO is significant and may be a better option than systemic therapies.https://vcm.edpsciences.org/articles/vcm/full_html/2022/01/vcm20220002/vcm20220002.htmlfolfoxarterial chemotherapyadvanced hepatocellular carcinoma |
| spellingShingle | Lyu Ning Zhao Ming Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study Visualized Cancer Medicine folfox arterial chemotherapy advanced hepatocellular carcinoma |
| title | Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study |
| title_full | Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study |
| title_fullStr | Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study |
| title_full_unstemmed | Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study |
| title_short | Another treatment option for locally advanced hepatocellular carcinoma: Interventional arterial infusion of FOLFOX chemotherapy from the FOHAIC-1 study |
| title_sort | another treatment option for locally advanced hepatocellular carcinoma interventional arterial infusion of folfox chemotherapy from the fohaic 1 study |
| topic | folfox arterial chemotherapy advanced hepatocellular carcinoma |
| url | https://vcm.edpsciences.org/articles/vcm/full_html/2022/01/vcm20220002/vcm20220002.html |
| work_keys_str_mv | AT lyuning anothertreatmentoptionforlocallyadvancedhepatocellularcarcinomainterventionalarterialinfusionoffolfoxchemotherapyfromthefohaic1study AT zhaoming anothertreatmentoptionforlocallyadvancedhepatocellularcarcinomainterventionalarterialinfusionoffolfoxchemotherapyfromthefohaic1study |